Literature DB >> 12243001

[Medical management of patients with benign paroxysmal positional vertigo].

M von Brevern1, F Lezius, K Tiel-Wilk, T Lempert.   

Abstract

Benign paroxysmal positional vertigo (BPPV) is the most common vestibular disorder which can be simply diagnosed. The evolution of highly effective positioning maneuvers has made BPPV the most successfully treatable cause of vertigo. We evaluated patients with BPPV with regard to past medical history and disease-related diagnostic and therapeutic procedures. Forty-two patients were recruited from a specialised dizziness clinic, and a further 29 patients were recruited from a neurological practice. The mean duration of the disease was 3.2 years, with an average of 2.4 episodes lasting typically several weeks to months. More than half of the patients felt severely disabled by BPPV. On average, three different medical specialities were consulted. Cerebral imaging (42%), caloric testing (46%), and audiometry (49%) were performed more often than diagnostic positioning (28%). Most patients received ineffective or no therapy, and only 4% were treated with a specific therapeutic positioning maneuver. Benign paroxysmal positional vertigo is a long-lasting and frequently recurrent disease which leads to significant morbidity and medical costs. The recent progress in the diagnosis and therapy of BPPV has not yet been widely established in medical practice in Germany.

Entities:  

Mesh:

Year:  2002        PMID: 12243001     DOI: 10.1007/s00115-002-1311-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  2 in total

Review 1.  [Benign paroxysmal positional vertigo].

Authors:  M von Brevern; T Lempert
Journal:  Nervenarzt       Date:  2004-09-11       Impact factor: 1.214

2.  [Benign paroxysmal positional vertigo with and without manifest positional nystagmus: an 18-month follow-up study of 70 patients].

Authors:  E Anagnostou; D Mandellos; A Patelarou; D Anastasopoulos
Journal:  HNO       Date:  2007-03       Impact factor: 1.284

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.